The company announced this on Thursday in Cambridge (US state of Massachusetts).
Moderna now expects sales from pre-agreed purchase agreements for the corona vaccine to be around $18 billion to $19 billion in 2022. The group had previously pledged about $21 billion.
For Moderna, the corona pandemic tailwind could likely abate further in 2023: According to the company, only $4.5 to $5.5 billion worth of acquisition deals have been signed so far – up to three billion attributable to delayed deliveries. However, management expects more – unspecified – sales in the most important sales markets.
In the third quarter, the group fell short of analysts’ expectations: Sales fell by a third to $3.1 billion. As a result, Moderna earned $1.04 billion – profits more than tripled a year ago.
(SDA)